Opko Health Inc (OPK) Options Open Interest

Monitoring OPK open interest helps you see where real money is positioned on Opko Health Inc's options and which strikes are attracting the most commitment from traders. Opko Health Inc's open interest reflects the total number of outstanding contracts that have not been closed or exercised, making it a powerful gauge of liquidity, conviction, and potential support and resistance zones. Use our scanner to monitor OPK options open interest in real time and find the strikes that matter.

Open interest is distinct from volume: volume counts how many contracts are traded in a session, while open interest counts how many remain open at the end of the day. Rising OPK options open interest alongside rising volume suggests new positions are being built, while falling open interest signals positions are being closed. Heavy open interest at specific strikes often acts as a magnet near expiration and can hint at where dealers and large traders expect Opko Health Inc to settle.

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers and governmental units; and a novel diagnostic instrument system to provide blood test results in the point-of-care setting, as well as 4Kscore prostate cancer testing services.

Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and associated obesity that is in Phase IIb trials; and hGH-CTP, a once-weekly human growth hormone injection that completed Phase III clinical trial in partnership with Pfizer, Inc. This segment develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins. The company also offers specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and imports, markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. In addition, it operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 1991 and is headquartered in Miami, Florida.

Pin risk into expiration, dealer positioning, liquidity checks for large orders — all of it starts with knowing where OPK open interest is concentrated. Our scanner maps Opko Health Inc's open interest across every strike and expiry, flags unusual buildups, and lets you drill into the contracts that institutional money is actually holding. Trade Opko Health Inc's options open interest as the signal it is, not as an afterthought.